These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1034 related items for PubMed ID: 34538770

  • 21. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer.
    Scholte M, Barentsz JO, Sedelaar JPM, Gotthardt M, Grutters JPC, Rovers MM.
    Eur Urol Focus; 2020 Sep 15; 6(5):967-974. PubMed ID: 30826284
    [Abstract] [Full Text] [Related]

  • 22. Ga68-PSMA PET for lymph node staging in intermediate and high-risk prostate cancer patients undergoing robotic assisted radical prostatectomy.
    Spena G, Moretti TB, Dávila FS, Dos Anjos G, Khan I, Calace FP, Aveta A, Pandolfo SD, Tufano A, Izzo A, Farias A, Perdonà S, Maes K.
    Minerva Urol Nephrol; 2024 Aug 15; 76(4):467-473. PubMed ID: 39051893
    [Abstract] [Full Text] [Related]

  • 23. The Role of 68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Intermediate/High Risk Patients With Prostate Cancer: A Diagnostic Meta-Analysis.
    Tu X, Zhang C, Liu Z, Shen G, Wu X, Nie L, Chang T, Xu H, Bao Y, Yang L, Wei Q.
    Front Oncol; 2020 Aug 15; 10():1365. PubMed ID: 33014777
    [Abstract] [Full Text] [Related]

  • 24. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ.
    BJU Int; 2020 Feb 15; 125(2):206-214. PubMed ID: 31680398
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
    Wong LM, Sutherland T, Perry E, Tran V, Spelman T, Corcoran N, Lawrentschuk N, Woo H, Lenaghan D, Buchan N, Bax K, Symons J, Saeed Goolam A, Chalasani V, Hegarty J, Thomas L, Christov A, Ng M, Khanani H, Lee SF, Taubman K, Tarlinton L.
    Eur Urol Oncol; 2024 Oct 15; 7(5):1015-1023. PubMed ID: 38281891
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.
    Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, Tay KJ, Tuan J, Thang SP, Lam W, Yuen J, Lawrentschuk N, Hofman MS, Murphy DG, Chen K.
    Eur Urol; 2023 Jul 15; 84(1):36-48. PubMed ID: 37032189
    [Abstract] [Full Text] [Related]

  • 30. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.
    van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.
    BJU Int; 2019 Jul 15; 124(1):62-68. PubMed ID: 30074667
    [Abstract] [Full Text] [Related]

  • 31. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
    Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A.
    Eur Urol; 2020 Dec 15; 78(6):779-782. PubMed ID: 32624281
    [Abstract] [Full Text] [Related]

  • 32. Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.
    Jansen BHE, Bodar YJL, Zwezerijnen GJC, Meijer D, van der Voorn JP, Nieuwenhuijzen JA, Wondergem M, Roeleveld TA, Boellaard R, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN.
    Eur J Nucl Med Mol Imaging; 2021 Feb 15; 48(2):509-520. PubMed ID: 32789599
    [Abstract] [Full Text] [Related]

  • 33. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Feb 15; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 34. 18 F-prostate specific membrane antigen positron emission tomography/computerized tomography for lymph node staging in medium/high risk prostate cancer: A systematic review and meta-analysis.
    Lv Z, Song L, Wang M, Hou H, Li H, Wang X, Wang J, Wang J, Liu M.
    Chin Med J (Engl); 2024 Apr 20; 137(8):949-958. PubMed ID: 37690993
    [Abstract] [Full Text] [Related]

  • 35. A retrospective study assessing the accuracy of [18F]-fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection.
    Puterman C, Bjöersdorff M, Amidi J, Anand A, Soller W, Jiborn T, Kjölhede H, Trägårdh E, Bjartell A.
    Scand J Urol; 2021 Aug 20; 55(4):293-297. PubMed ID: 33939583
    [Abstract] [Full Text] [Related]

  • 36. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer.
    Hinsenveld FJ, Wit EMK, van Leeuwen PJ, Brouwer OR, Donswijk ML, Tillier CN, Vegt E, van Muilekom E, van Oosterom MN, van Leeuwen FWB, van der Poel HG.
    J Nucl Med; 2020 Apr 20; 61(4):540-545. PubMed ID: 31562222
    [Abstract] [Full Text] [Related]

  • 37. Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.
    Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H.
    J Transl Med; 2017 Nov 07; 15(1):230. PubMed ID: 29115970
    [Abstract] [Full Text] [Related]

  • 38. Development and external validation of a multivariable [68Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer.
    Muehlematter UJ, Schweiger L, Ferraro DA, Hermanns T, Maurer T, Heck MM, Rupp NJ, Eiber M, Rauscher I, Burger IA.
    Eur J Nucl Med Mol Imaging; 2023 Aug 07; 50(10):3137-3146. PubMed ID: 37261472
    [Abstract] [Full Text] [Related]

  • 39. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
    Baas DJH, Schilham M, Hermsen R, de Baaij JMS, Vrijhof HJEJ, Hoekstra RJ, Sedelaar JPM, Küsters-Vandevelde HVN, Gotthardt M, Wijers CHW, van Basten JP, Somford DM.
    Prostate Cancer Prostatic Dis; 2022 Mar 07; 25(1):65-70. PubMed ID: 34471231
    [Abstract] [Full Text] [Related]

  • 40. Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
    Kawada T, Yanagisawa T, Rajwa P, Sari Motlagh R, Mostafaei H, Quhal F, Laukhtina E, Aydh A, König F, Pallauf M, Pradere B, Ceci F, Baltzer PAT, Hacker M, Rasul S, Karakiewicz PI, Araki M, Nasu Y, Shariat SF.
    Eur Urol Oncol; 2022 Aug 07; 5(4):390-400. PubMed ID: 35715320
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.